Trial of L-DOPA as a Treatment to Improve Vision in Albinism

Completed · Phase 2 · Has a placebo group

Conditions studied: Albinism

In brief

This project will evaluate the effect of two doses of levodopa (L-DOPA) in a randomized, placebo-controlled, double-masked clinical trial to see if vision can be improved in individuals with albinism. The hypothesis is that providing L-DOPA to the retinas of these individuals may increase melanin pigment production. Increased melanin has previously been shown to be associated with improved vision.

Key facts

Study ID

NCT01176435

Run by

University of Minnesota

People needed

45

Starts

2010-09-01

Expected to finish

2014-12-01

Last updated by the study team

2018-05-02

Who can join

Age: 3 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 3 to 60 years with albinism

You may not qualify if…

• Glaucoma or at increased risk of glaucoma
• History of dystonia
• History of melanoma
• Planning to undergo eye muscle surgery during study time frame
• Undergoing vision therapy
• Taking iron supplements or vitamins with iron
• Taking medication for ADHD
• Known liver or gastrointestinal disease
• Previous treatment with levodopa
• Psychological problems
• Ocular abnormalities other than those associated with albinism
• Pregnant, nursing or planning to become pregnant during study
• Known allergy to levodopa/carbidopa

Where it is running

• University of Minnesota Eye Clinic — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.